|
Expert Questions Pfizer’s Reporting of Neurontin Trial Results
A medical journal review that found selective publishing of study data for Pfizer’s Neurontin for off-label use — when results were not statistically significant for the primary outcome the protocol specified — reveals a practice that should at least be justified and documented, an expert says.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives